Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects

Secondary Hyperparathyroidism: Pathogenesis, Disease Progression, and Therapeutic Options

(2011) J. Cunningham et al.   Clinical Journal of the American Society of Nephrology

FGF23 induces left ventricular hypertrophy

(2011) Christian Faul et al.   JOURNAL OF CLINICAL INVESTIGATION

Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism

(2011) M. Koizumi et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Identification of calcium sensing receptor (CaSR) mRNA-expressing cells in normal and injured rat brain

(2009) Giuseppa Mudò et al.   BRAIN RESEARCH

Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease

(2009) Orlando M. Gutiérrez et al.   CIRCULATION

Effects of Cinacalcet and Concurrent Low-Dose Vitamin D on FGF23 Levels in ESRD

(2009) J. B. Wetmore et al.   Clinical Journal of the American Society of Nephrology

Clinical Pharmacokinetic and Pharmacodynamic Profile of Cinacalcet Hydrochloride

(2009) Desmond Padhi et al.   CLINICAL PHARMACOKINETICS

Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients

(2009) Yekaterina GINCHERMAN et al.   Hemodialysis International

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Participants With CKD Not Receiving Dialysis

(2008) Michel Chonchol et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences

(2008) G. Jean et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis

(2008) Orlando M. Gutiérrez et al.   NEW ENGLAND JOURNAL OF MEDICINE